Navigation Links
PAREXEL Receives BioSingapore Award for Best Performing CRO

BOSTON, March 23 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has received the Best Performing Clinical Research Organization (CRO) Award from BioSingapore, an industry association for life sciences businesses encouraged by the Economic Development Board of Singapore. The award was presented to PAREXEL at the BioSingapore Asia/Pacific Biotechnology Awards 2009 Gala Dinner held March 17, 2009 during the BioMedical Asia Conference in Singapore. BioSingapore's Awards celebrate the contributions of companies and individuals in the life sciences industry to advancing the scientific enterprise in the Asia/Pacific region.

According to Michael Entzeroth, Ph.D., Chairman of BioSingapore, "The BioSingapore Award for Best Performing CRO, which was reviewed by an independent panel of peer judges, honors PAREXEL for its focus on supporting clinical development throughout the Asia/Pacific region. PAREXEL is recognized for the broad spectrum of services provided by the Company, the competitive edge it has created in this geography, and its international reputation for speed and high quality. BioSingapore is pleased to commend PAREXEL for its overall outstanding performance and contributions to advancing the clinical research environment in the Asia/Pacific region."

"PAREXEL is honored to be chosen as the Best Performing CRO by BioSingapore," said Mark A. Goldberg, M.D., Chief Operating Officer of PAREXEL International. "PAREXEL has had a long-term commitment to providing high quality clinical development services in the Asia/Pacific region. As outsourced clinical research experiences accelerated growth in this geography, we look forward to continuing to provide both global capabilities and local expertise to meet client needs in developing safe and efficacious treatments. This achievement would not have been possible without the dedication of our talented employees and the ongoing support of our valued clients in the region."

For more information about PAREXEL's capabilities in the Asia/Pacific region visit More information about BioSingapore can be found at

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 51 countries around the world, and has over 9,250 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2008 as filed with the SEC on February 9, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Jennifer Baird, Senior Director of Public Relations
    PAREXEL International
    Tel: +781-434-4409

    Rebecca Passo
    SHIFT Communications
    Tel: +617-779-1817

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
2. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
3. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
4. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
5. PAREXEL International to Present at the 27th Annual JP Morgan Healthcare Conference
6. PAREXEL Receives Best CRO Award from Scrip
7. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
8. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
9. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
10. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
11. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
Breaking Biology Technology:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
Breaking Biology News(10 mins):